{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:17:13Z","timestamp":1780474633824,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.biopha.2018.04.077","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T18:12:20Z","timestamp":1524593540000},"page":"546-552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Tert-butyl 4-((1-phenyl-1H-pyrazol-4-yl) methyl) piperazine-1-carboxylate (LQFM104)\u2013 New piperazine derivative with antianxiety and antidepressant-like effects: Putative role of serotonergic system"],"prefix":"10.1016","volume":"103","author":[{"given":"Dayane Moreira","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boniek Gontijo","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1vio Silva","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano Morais","family":"Li\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danillo Ramos","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorrane Kelle da Silva","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina Sofia","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane Ferreira","family":"de Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiany Priscilla Bueno","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Fagundes","family":"da Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ianca Gontijo Cavalcante","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablinny Moreira","family":"Galdino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elson Alves","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Menegatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.04.077_bib0005","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/fcp.12186","article-title":"Treatment of anxiety and depression: medicinal plants in retrospect","volume":"30","author":"Fajemiroye","year":"2016","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0010","article-title":"Disability and quality of life impact of mental disorders in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project","volume":"420","author":"Alonso","year":"2004","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"289","key":"10.1016\/j.biopha.2018.04.077_bib0015","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2018.04.077_bib0020","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(07)61415-9","article-title":"Depression, chronic diseases, and decrements in health: results from the world health surveys","volume":"370","author":"Moussavi","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2018.04.077_bib0025","first-page":"82","article-title":"The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles","volume":"24","author":"Ramasubbu","year":"2012","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.biopha.2018.04.077_bib0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.psc.2009.05.004","article-title":"The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology","volume":"32","author":"Martin","year":"2009","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.biopha.2018.04.077_bib0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0893-133X(01)00395-5","article-title":"Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration","volume":"26","author":"Hensler","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2018.04.077_bib0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-2999(97)00115-5","article-title":"Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test","volume":"325","author":"Redrobe","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0045","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cellsig.2004.12.007","article-title":"Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways","volume":"17","author":"Taylor","year":"2005","journal-title":"Cell Signal."},{"key":"10.1016\/j.biopha.2018.04.077_bib0050","first-page":"588","article-title":"Piperazine derivatives including the putative anxiolytic drugs, buspirone and ipsapirone, are agonists at 5-HT1A receptors negatively coupled with adenylate cyclase in hipocampal neurons","volume":"335","author":"Bockaert","year":"1987","journal-title":"Nauny-schimiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0055","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1021\/jm00091a004","article-title":"Structure-activity relationship studies of central nervous system agentes. 5. Effect of the hydrocarbon chain on the affinity of 4-substituted 1-(3-chlorophenyl) piperazine for 5-HT1A receptor site","volume":"35","author":"Mokrosz","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2018.04.077_bib0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FBP.0000000000000275","article-title":"Effects of the 5-HT1A receptor agonists buspirone and 8-OH-DPAT on pupil size in common marmosets","volume":"28","author":"Kotani","year":"2017","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/cbdd.12370","article-title":"Design, synthesis, and pharmacological evaluation of novel 2-(4-substituted piperazin-1-yl)1, 8 naphthyridine 3-Carboxylic acids as 5-HT3 receptor antagonists for the management of depression","volume":"84","author":"Dhar","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.biopha.2018.04.077_bib0070","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1517\/13543776.2012.719878","article-title":"Phenylpiperazine derivatives: a patent review (2006 - present)","volume":"22","author":"Maia","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.biopha.2018.04.077_bib0075","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/13543776.2016.1189902","article-title":"Piperazine derivatives for therapeutic use: a patent review (2010-present)","volume":"26","author":"Rathi","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.biopha.2018.04.077_bib0080","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1039\/jr9570003024","article-title":"The preparation of some trinitrophenylpyrazoles","author":"Finar","year":"1957","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.biopha.2018.04.077_bib0085","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/cbdd.12961","article-title":"Anxiolytic-like effect of 2-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)ethan-1-ol is mediated through the benzodiazepine and nicotinic pathways","volume":"90","author":"Brito","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.biopha.2018.04.077_bib0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.physbeh.2013.08.019","article-title":"Effects of imperatorin on nicotine-induced anxiety- and memory-related responses and oxidative stress in mice","volume":"122","author":"Budzynska","year":"2013","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.biopha.2018.04.077_bib0095","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.biopha.2018.04.077_bib0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.pnpbp.2014.06.001","article-title":"The antidepressant-like effect of 7-fluoro-1,3-diphenylisoquinoline-1-amine in the mouse forced swimming test is mediated by serotonergic and dopaminergic systems","volume":"54","author":"Pesarico","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2018.04.077_bib0105","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.pnpbp.2009.02.003","article-title":"Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission","volume":"33","author":"Binfar\u00e9","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2018.04.077_bib0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","article-title":"The open field as a paradigm to measure the effects of drugs on anxiety-like beehaviors: a review","volume":"463","author":"Prut","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0115","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nprot.2007.44","article-title":"The use of the elevated plus maze as an assay of anxiety-related behavior in rodents","volume":"2","author":"Walf","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biopha.2018.04.077_bib0120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0091-3057(97)00279-7","article-title":"Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190","volume":"58","author":"Cao","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.biopha.2018.04.077_bib0125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0166-4328(96)00118-0","article-title":"Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist","volume":"73","author":"Fletcher","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2018.04.077_bib0130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/416396a","article-title":"Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult","volume":"416","author":"Gross","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2018.04.077_bib0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejphar.2003.09.064","article-title":"Anxiolytic-like effects of the selective 5-HT1A receptor antagonist WAY 100635 in non-human primates","volume":"482","author":"Barros","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.brainres.2004.07.041","article-title":"Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test","volume":"1023","author":"Zomkowski","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2018.04.077_bib0145","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00213-007-0728-9","article-title":"Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test","volume":"192","author":"O\u2019Leary","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopha.2018.04.077_bib0150","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1097\/00001756-200006260-00008","article-title":"Acute treatments with GMP produce antidepressant-like effects in mice","volume":"11","author":"Eckeli","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.biopha.2018.04.077_bib0155","doi-asserted-by":"crossref","first-page":"324063","DOI":"10.1155\/2014\/324063","article-title":"Antidepressant effects of Mallotus oppositifolius in acute murine models","volume":"2014","author":"Kukuia","year":"2014","journal-title":"ISRN Pharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0160","doi-asserted-by":"crossref","first-page":"397943","DOI":"10.1155\/2015\/397943","article-title":"Antidepressant-Like effect of the leaves of Pseudospondias microcarpa in mice: evidence for the involvement of the serotoninergic system, NMDA receptor complex, and nitric oxide pathway","volume":"2015","author":"Adongo","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.biopha.2018.04.077_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130050638","article-title":"Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity","volume":"138","author":"Redrobe","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopha.2018.04.077_bib0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lfs.2015.11.009","article-title":"Involvement of the monoamine system in antidepressant-like properties of 4-(1-phenyl-1h-pyrazol-4-ylmethyl)-piperazine-1-carboxylic acid ethyl ester","volume":"143","author":"Galdino","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2018.04.077_bib0175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1601-5215.2012.00669.x","article-title":"5-HT depletion, but not 5-HT1A antagonist, prevents the anxiolytic-like effect of citalopram in rat contextual conditioned fear stress model","volume":"25","author":"Masuda","year":"2013","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.biopha.2018.04.077_bib0180","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00210-017-1451-7","article-title":"A new piperazine derivative: 1-(4-(3,5-di-tert-butyl-4-hydroxybenzyl) piperazin-1-yl)-2-methoxyethan-1-one with antioxidant and central activity","volume":"391","author":"Brito","year":"2018","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0185","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2018.04.077_bib0190","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s002130050074","article-title":"The serotonin-1A receptor antagonist WAY-100635 modifies fluoxetine\u2019s antidepressant-like profile on the differential reinforcement of low rates 72-s schedule in rats","volume":"148","author":"Cousins","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2018.04.077_bib0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0014-2999(01)01011-1","article-title":"5-HT1A receptor activation and antidepressant-like effects: F13714 has high efficacy and marked antidepressant potential","volume":"25","author":"Koek","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.euroneuro.2004.01.004","article-title":"5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat","volume":"14","author":"De Vry","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0205","series-title":"Avalia\u00e7\u00e3o farmacol\u00f3gica no sistema nervoso central de um novo derivado piperaz\u00ednico LQFM104","first-page":"54","author":"Rodrigues","year":"2015"},{"key":"10.1016\/j.biopha.2018.04.077_bib0210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.neubiorev.2014.03.007","article-title":"Serotonin in anxiety and panic: contributions of the elevated T-maze","volume":"46","author":"Zangrossi","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.biopha.2018.04.077_bib0215","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00213-013-3389-x","article-title":"5-HT1A receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function","volume":"231","author":"Garcia-Garcia","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2018.04.077_bib0220","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/nn.4116","article-title":"5-HT1A receptors on mature dentate gyrus granule cells are critical for the antidepressant response","volume":"18","author":"Samuels","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.biopha.2018.04.077_bib0225","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1098\/rstb.2012.0038","article-title":"Serotonin receptor expression along the dorsal-ventral axis of mouse hippocampus","volume":"367","author":"Tanaka","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.biopha.2018.04.077_bib0230","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1083328","article-title":"Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants","volume":"301","author":"Santarelli","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.biopha.2018.04.077_bib0235","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.neuroscience.2005.05.056","article-title":"The role of 5-HT1A receptors in the proliferation and survival of progenitor cells in the dentate gyrus of the adult hippocampus and their regulation by corticoids","volume":"135","author":"Huang","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2018.04.077_bib0240","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0006-8993(02)03477-7","article-title":"5-HT1A receptor antagonist administration decreases cell proliferation in the dentate gyrus","volume":"955","author":"Radley","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2018.04.077_bib0245","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1017\/S1461145709991222","article-title":"F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity","volume":"13","author":"Assi\u00e9","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2018.04.077_bib0250","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.7b00443","article-title":"Activity of serotonin 5-HT1A receptor biased agonists in rat: anxiolytic and antidepressant-like properties","author":"Jastrz\u0119bska-Wi\u0119sek","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2018.04.077_bib0255","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1523\/JNEUROSCI.5836-10.2011","article-title":"Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety","volume":"31","author":"Richardson-Jones","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2018.04.077_bib0260","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/cbdd.12394","article-title":"Synthesis and evaluation of antidepressant-like activity of some 4-Substituted 1-(2-methoxyphenyl)piperazine derivatives","volume":"85","author":"Waszkielewicz","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.biopha.2018.04.077_bib0265","unstructured":"U. S. Food & Drug. Drug Approvals and Databases. https:\/\/www.fda.gov\/drugs\/informationondrugs\/ (Accessed 22 September 2017)."},{"key":"10.1016\/j.biopha.2018.04.077_bib0270","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.lfs.2012.04.037","article-title":"Central pharmacological activity of a new piperazine derivative: 4-(1-phenyl-1h-pyrazol-4-ylmethyl)-piperazine-1-carboxylic acid ethyl ester","volume":"90","author":"De Brito","year":"2012","journal-title":"Life Sci."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217357074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217357074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T01:27:16Z","timestamp":1720661236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217357074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":54,"alternative-id":["S0753332217357074"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.04.077","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tert-butyl 4-((1-phenyl-1H-pyrazol-4-yl) methyl) piperazine-1-carboxylate (LQFM104)\u2013 New piperazine derivative with antianxiety and antidepressant-like effects: Putative role of serotonergic system","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.04.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}